Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus

Published:2017-10-02 Issue:4 Volume:9 Page:347-360
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Marchenko Olga¹,Jiang Qi²,Chuang-Stein Christy³,Mehta Cyrus⁴,Levenson Mark⁵,Russek-Cohen Estelle⁶,Liu Lingyun⁴,Sanchez-Kam Matilde⁷,Zink Richard⁸,Ke Chunlei²,Ma Haijun²,Maca Jeff¹,Park Soomin⁹

Affiliation:

1. Quintiles, Durham, NC

2. Amgen, Thousand Oaks, CA

3. Chuang-Stein Consulting, Kalamazoo, MI

4. Cytel, Cambridge, MA

5. CDER, FDA, Silver Spring, MD

6. CBER, FDA, Silver Spring MD

7. Arena Pharmaceuticals, Zofingen, Switzerland

8. JMP Life Sciences, SAS Institute, Cary, NC; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC

9. Eli Lilly, Westfield, IN

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/19466315.2017.1280411

Reference35 articles.

1. Statistical Considerations on Subgroup Analysis in Clinical Trials

2. Graphical approaches to the analysis of safety data from clinical trials

3. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

4. Accounting for Multiplicities in Assessing Drug Safety: A Three-Level Hierarchical Mixture Model

5. Intravenous Platelet Blockade with Cangrelor during PCI

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of Cardiovascular Outcomes Studies;Contemporary Cardiology;2024

2. Biostatistics in Clinical Trials;Quantitative Methods in Pharmaceutical Research and Development;2020

3. Interdisciplinary Safety Evaluation and Quantitative Safety Monitoring: Introduction to a Series of Papers;Therapeutic Innovation & Regulatory Science;2019-03-29

4. Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials;Therapeutic Innovation & Regulatory Science;2018-03

5. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data;American Journal of Nephrology;2018